352 related articles for article (PubMed ID: 21433318)
21. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
22. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.
Kondo T; Okuno N; Naruse H; Kishimoto M; Tasaka T; Tsujioka T; Matsuoka A; Sugihara T; Tohyama Y; Tohyama K
Leuk Lymphoma; 2008 Sep; 49(9):1784-91. PubMed ID: 18661406
[TBL] [Abstract][Full Text] [Related]
23. Molecular diagnostics of myeloproliferative neoplasms.
Langabeer SE; Andrikovics H; Asp J; Bellosillo B; Carillo S; Haslam K; Kjaer L; Lippert E; Mansier O; Oppliger Leibundgut E; Percy MJ; Porret N; Palmqvist L; Schwarz J; McMullin MF; Schnittger S; Pallisgaard N; Hermouet S;
Eur J Haematol; 2015 Oct; 95(4):270-9. PubMed ID: 25951317
[TBL] [Abstract][Full Text] [Related]
24. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U; Luthra R; Medeiros LJ; Patel KP
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
[TBL] [Abstract][Full Text] [Related]
26. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.
Morotti A; Rocca S; Carrà G; Saglio G; Brancaccio M
Blood Rev; 2017 May; 31(3):139-150. PubMed ID: 27899218
[TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
[TBL] [Abstract][Full Text] [Related]
28. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Ragon BK; Savona MR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
[TBL] [Abstract][Full Text] [Related]
29. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
30. Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know.
Hasserjian RP
Curr Opin Hematol; 2018 Mar; 25(2):120-128. PubMed ID: 29256927
[TBL] [Abstract][Full Text] [Related]
31. New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms.
Passamonti F; Mora B; Maffioli M
Curr Opin Hematol; 2016 Mar; 23(2):137-43. PubMed ID: 26825696
[TBL] [Abstract][Full Text] [Related]
32. [Review of changes introduced by the new WHO classification (4th edition) of myeloid neoplasms. An overview].
Komatsu N
Rinsho Ketsueki; 2009 Mar; 50(3):127-33. PubMed ID: 19352078
[No Abstract] [Full Text] [Related]
33. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
34. WHO classification of myeloid neoplasms and leukemia.
Wandt H; Haferlach T; Thiede C; Ehninger G
Blood; 2010 Jan; 115(3):748-9; author reply 749-50. PubMed ID: 20093414
[No Abstract] [Full Text] [Related]
35. Molecular characterization of chronic myeloproliferative neoplasias in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
[TBL] [Abstract][Full Text] [Related]
36. [Classification of myeloid leukemias].
Kuriyama K
Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
[TBL] [Abstract][Full Text] [Related]
37. Update from the latest WHO classification of MPNs: a user's manual.
Passamonti F; Maffioli M
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
[TBL] [Abstract][Full Text] [Related]
38. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
39. FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report.
Chang K; Liu JH; Yu SC; Lin CW
Hum Pathol; 2018 Apr; 74():114-121. PubMed ID: 29107667
[TBL] [Abstract][Full Text] [Related]
40. Myeloid Neoplasms with Germline Predisposition.
Geyer JT
Pathobiology; 2019; 86(1):53-61. PubMed ID: 30048985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
